Medline Inc

Medline Inc (MDLN) Stock Analysis

$36.570

+0.651 (+1.78%)At close

Loading chart…
High
36.865
Open
35.880
VWAP
36.44
Volume
7.66M
Mkt Cap
—
Low
35.880
Amount
279.12M
EV/EBITDA, TTM
45.11

Medline Inc. is a provider of medical-surgical products and supply chain solutions serving all points of care. The Company delivers mission-critical products used daily across the full range of care settings, from hospitals and surgery centers to physician offices and post-acute facilities. It operates through two segments: Medline Brand and Supply Chain Solutions. These segments offer approximately 335,000 medical-surgical products, including surgical and procedural kits, gloves and protective apparel, urological and incontinence care, wound care, and consumable lab and diagnostics products. Its Medline Brand products are organized into three product categories: Front Line Care, Surgical Solutions, and Laboratory and Diagnostics. The Supply Chain Solutions segment procures and distributes a variety of third-party products from national brands and also provides tailored logistics and supply chain optimization services to domestic and international consumers.

AI analysis of Medline Inc (MDLN)

Hold

Medline Inc. is currently a hold. The stock is priced at $36.26, with an RSI of 76.377 indicating it may be overbought. Despite a positive 1-year change of +25.03%, the recent drop of over 16% in stock price due to lowered EBITDA outlook raises concerns. The forward P/E ratio of 20.92 suggests a premium valuation, and the gross margin has recently improved to 26.52%, but risks remain high due to ongoing investigations and market pressures.

Valuation Metrics

The current forward P/E ratio for Medline Inc (MDLN) is 20.92, compared to its 5-year average forward P/E of 30.88.

Forward P/E

Fair
5Y Average P/E
30.88
Current P/E
20.92
Overvalued
44.44
Undervalued
17.32

Forward EV/EBITDA

Overvalued
5Y Average EV/EBITDA
27.98
Current EV/EBITDA
45.11
Overvalued
43.62
Undervalued
12.34

Forward P/S

Fair
5Y Average P/S
1.46
Current P/S
1.44
Overvalued
1.95
Undervalued
0.96

Whales holding MDLN

B

Banque Pictet & Cie SA

+ HoldingMDLN

+11.97%

3M Return

A

Alyeska Investment Group, L.P.

+ HoldingMDLN

+5.05%

3M Return

B

BW Gestao de Investimentos Ltda.

+ HoldingMDLN

+4.46%

3M Return

S

Soros Fund Management LLC

+ HoldingMDLN

+3.34%

3M Return

B

BEA Union Investment Management Limited

+ HoldingMDLN

+2.85%

3M Return

H

HBK Investments L.P.

+ HoldingMDLN

+2.71%

3M Return

Events Timeline

2026-10-15 (ET)

14:30:00

Medline Announces New Distribution Center in Michigan

2026-08-05 (ET)

08:30:00

Company Raises 2026 Organic Sales Growth Outlook to 9.0%-10.0%

08:30:00

Medline Reports Q2 Revenue of $7.69B

2026-07-08 (ET)

11:30:00

Medline Signs New Prime Vendor Agreement with Allina Health

2026-07-06 (ET)

12:00:00

Medline Signs New Warehouse Lease in California, Expands 45%

News

MDLN FAQ — answered by Alphio AI

Medline Inc. is a provider of medical-surgical products and supply chain solutions serving all points of care. The Company delivers mission-critical products used daily across the full range of care settings, from hospitals and surgery centers to physician offices and post-acute facilities. It operates through two segments: Medline Brand and Supply Chain Solutions. These segments offer approximately 335,000 medical-surgical products, including surgical and procedural kits, gloves and protective apparel, urological and incontinence care, wound care, and consumable lab and diagnostics products. Its Medline Brand products are organized into three product categories: Front Line Care, Surgical Solutions, and Laboratory and Diagnostics. The Supply Chain Solutions segment procures and distributes a variety of third-party products from national brands and also provides tailored logistics and supply chain optimization services to domestic and international consumers. It operates in the Healthcare sector.

Medline Inc. is currently a hold. The stock is priced at $36.26, with an RSI of 76.377 indicating it may be overbought. Despite a positive 1-year change of +25.03%, the recent drop of over 16% in stock price due to lowered EBITDA outlook raises concerns. The forward P/E ratio of 20.92 suggests a premium valuation, and the gross margin has recently improved to 26.52%, but risks remain high due to ongoing investigations and market pressures.

Community

More ↗

No posts yet

Sign up or log in to join the discussion

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading